Download PDF
Hamostaseologie 2019; 39(03): 227-237
DOI: 10.1055/s-0039-1678732
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Pathophysiology of Autoimmune Thrombocytopenia: Current Insight with a Focus on Thrombopoiesis

Irene Marini
1   Department of Transfusion Medicine, Medical Faculty of Tübingen, University of Tübingen, Tübingen, Germany
,
Tamam Bakchoul
1   Department of Transfusion Medicine, Medical Faculty of Tübingen, University of Tübingen, Tübingen, Germany
› Author Affiliations
Further Information

Publication History

19 July 2018

08 January 2019

Publication Date:
25 February 2019 (online)

Also available at
   Permissions and Reprints

Abstract

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a significant reduction in the number of circulating platelets which is frequently associated with bleeding. The total count of platelets in the body is finely regulated by the balance between platelet production and destruction. Although the pathogenesis of ITP is still not completely elucidated, it is largely recognized that the low platelet count observed in ITP patients is due to alterations of both mechanisms. An abnormal proliferation of autoreactive T cells leading to the breakdown of immune tolerance to platelet antigens is suggested to be responsible for the up-regulated proliferation of autoantibody producing B cells. Consequently, the immune response induces enhanced T cell-mediated cytotoxicity and antibody-mediated platelet destruction through phagocytosis, complement activation and apoptosis. An additional contribution to the pathophysiology of ITP is given by alterations of thrombopoiesis caused by platelet-reactive autoantibodies or cytotoxic T cells leading to impaired megakaryocyte differentiation and platelet production. All these processes involved in ITP pathophysiology account for the complexity and heterogeneity in the clinical manifestation and therapy responsiveness of this disorder. For this reason, a better understanding of the different underlying mechanisms in ITP is necessary to develop more efficient therapeutic treatments in the future. In this review, we will provide an update on the pathophysiology of ITP with a particular focus on the impact of impaired thrombopoiesis.

Keywords

autoantibodies - platelet - megakaryocytes - autoimmune disorders - acquired thrombocytopenia

Author Contributions

Irene Marini did the literature search and wrote the sections on alterations of megakaryopoiesis and thrombopoiesis. Tamam Bakchoul contributed to the subsections on the antibody-mediated platelet clearance. Both authors approved the final version of the manuscript.


 

  • References

  • 1 Provan D, Stasi R, Newland AC. , et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (02) 168-186
    CrossrefPubMedGoogle Scholar
  • 2 Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA. ; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117 (16) 4190-4207
    CrossrefPubMedGoogle Scholar
  • 3 Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014; 124 (22) 3308-3315
    PubMedGoogle Scholar
  • 4 Bennett CM, Neunert C, Grace RF. , et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer 2018;65(1)
    PubMedGoogle Scholar
  • 5 Cines DB, Liebman HA. The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation. Hematol Oncol Clin North Am 2009; 23 (06) 1155-1161
    CrossrefPubMedGoogle Scholar
  • 6 D'Orazio JA, Neely J, Farhoudi N. ITP in children: pathophysiology and current treatment approaches. J Pediatr Hematol Oncol 2013; 35 (01) 1-13
    CrossrefPubMedGoogle Scholar
  • 7 McKenzie CG, Guo L, Freedman J, Semple JW. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol 2013; 163 (01) 10-23
    CrossrefPubMedGoogle Scholar
  • 8 Takahashi T, Yujiri T, Tanizawa Y. Helicobacter pylori and chronic ITP: the discrepancy in the clinical responses to eradication therapy might be due to differences in the bacterial strains. Blood 2004; 104 (02) 594
    PubMedGoogle Scholar
  • 9 Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol 2005; 129 (06) 818-824
    CrossrefPubMedGoogle Scholar
  • 10 Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci 1965; 124 (02) 499-542
    PubMedGoogle Scholar
  • 11 Ku FC, Tsai CR, Der Wang J, Wang CH, Chang TK, Hwang WL. Stromal-derived factor-1 gene variations in pediatric patients with primary immune thrombocytopenia. Eur J Haematol 2013; 90 (01) 25-30
    CrossrefPubMedGoogle Scholar
  • 12 Rank A, Weigert O, Ostermann H. Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics 2010; 4: 139-145
    PubMedGoogle Scholar
  • 13 Zhao Z, Yang L, Yang G. , et al. Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia. PLoS One 2015; 10 (05) e0126601
    CrossrefPubMedGoogle Scholar
  • 14 Ji X, Zhang L, Peng J, Hou M. T cell immune abnormalities in immune thrombocytopenia. J Hematol Oncol 2014; 7: 72
    CrossrefPubMedGoogle Scholar
  • 15 Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6 (04) 345-352
    CrossrefPubMedGoogle Scholar
  • 16 Sakakura M, Wada H, Tawara I. , et al. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 2007; 120 (02) 187-193
    CrossrefPubMedGoogle Scholar
  • 17 Liu B, Zhao H, Poon MC. , et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007; 78 (02) 139-143
    PubMedGoogle Scholar
  • 18 Hemdan NY, Birkenmeier G, Wichmann G. , et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev 2010; 9 (11) 785-792
    CrossrefPubMedGoogle Scholar
  • 19 Ma D, Zhu X, Zhao P. , et al. Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann Hematol 2008; 87 (11) 899-904
    CrossrefPubMedGoogle Scholar
  • 20 Ma L, Simpson E, Li J. , et al. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. Blood 2015; 126 (02) 247-256
    PubMedGoogle Scholar
  • 21 Nishimoto T, Satoh T, Simpson EK, Ni H, Kuwana M. Predominant autoantibody response to GPIb/IX in a regulatory T-cell-deficient mouse model for immune thrombocytopenia. J Thromb Haemost 2013; 11 (02) 369-372
    CrossrefPubMedGoogle Scholar
  • 22 Veneri D, De Matteis G, Solero P. , et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment. Platelets 2005; 16 (05) 307-311
    CrossrefPubMedGoogle Scholar
  • 23 Kim J, Park CJ, Chi HS. , et al. Idiopathic thrombocytopenic purpura: better therapeutic responses of patients with B- or T-cell clonality than patients without clonality. Int J Hematol 2003; 78 (05) 461-466
    CrossrefPubMedGoogle Scholar
  • 24 Zhao C, Li X, Zhang F, Wang L, Peng J, Hou M. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008; 93 (09) 1428-1430
    CrossrefPubMedGoogle Scholar
  • 25 Chapman LM, Aggrey AA, Field DJ. , et al. Platelets present antigen in the context of MHC class I. J Immunol 2012; 189 (02) 916-923
    CrossrefPubMedGoogle Scholar
  • 26 Zhang F, Chu X, Wang L. , et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006; 76 (05) 427-431
    CrossrefPubMedGoogle Scholar
  • 27 Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 1998; 102 (07) 1393-1402
    CrossrefPubMedGoogle Scholar
  • 28 Stasi R, Del Poeta G, Stipa E. , et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110 (08) 2924-2930
    PubMedGoogle Scholar
  • 29 Olsson B, Andersson PO, Jernås M. , et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9 (09) 1123-1124
    CrossrefPubMedGoogle Scholar
  • 30 Daridon C, Loddenkemper C, Spieckermann S. , et al. Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia. Blood 2012; 120 (25) 5021-5031
    PubMedGoogle Scholar
  • 31 Olsson B, Ridell B, Jernås M, Wadenvik H. Increased number of B-cells in the red pulp of the spleen in ITP. Ann Hematol 2012; 91 (02) 271-277
    CrossrefPubMedGoogle Scholar
  • 32 Youinou P, Pers JO. The late news on baff in autoimmune diseases. Autoimmun Rev 2010; 9 (12) 804-806
    CrossrefPubMedGoogle Scholar
  • 33 Zhou Z, Chen Z, Li H. , et al. BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura. Autoimmunity 2009; 42 (02) 112-119
    CrossrefPubMedGoogle Scholar
  • 34 Yang Q, Xu S, Li X. , et al. Pathway of toll-like receptor 7/B cell activating factor/B cell activating factor receptor plays a role in immune thrombocytopenia in vivo. PLoS One 2011; 6 (07) e22708
    CrossrefPubMedGoogle Scholar
  • 35 Yang Q, Wang B, Yu H. , et al. TLR7 promotes Th1 polarization in immune thrombocytopenia. Thromb Res 2011; 128 (03) 237-242
    CrossrefPubMedGoogle Scholar
  • 36 Li X, Zhong H, Bao W. , et al. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood 2012; 120 (16) 3318-3325
    PubMedGoogle Scholar
  • 37 Semple JW, Provan D. The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. Curr Opin Hematol 2012; 19 (05) 357-362
    CrossrefPubMedGoogle Scholar
  • 38 Blair PA, Noreña LY, Flores-Borja F. , et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32 (01) 129-140
    CrossrefPubMedGoogle Scholar
  • 39 Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012; 30: 221-241
    CrossrefPubMedGoogle Scholar
  • 40 Chen JF, Yang LH, Dong CX. , et al. Significance of detection of anti-GPIIb/IIIa antibody secreting B cells and platelet-specific antibody in patients with idiopathic thrombocytopenic purpura [in Chinese]. Zhonghua Xue Ye Xue Za Zhi 2010; 31 (09) 603-606
    PubMedGoogle Scholar
  • 41 Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38 (01) 1-10
    PubMedGoogle Scholar
  • 42 Stockelberg D, Hou M, Jacobsson S, Kutti J, Wadenvik H. Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA. Eur J Haematol 1996; 56 (1–2): 72-77
    PubMedGoogle Scholar
  • 43 He R, Reid DM, Jones CE, Shulman NR. Extracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. Blood 1995; 86 (10) 3789-3796
    CrossrefPubMedGoogle Scholar
  • 44 Kiefel V, Freitag E, Kroll H, Santoso S, Mueller-Eckhardt C. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol 1996; 72 (04) 280-285
    CrossrefPubMedGoogle Scholar
  • 45 McMillan R. The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura. Curr Hematol Rep 2005; 4 (02) 160-165
    PubMedGoogle Scholar
  • 46 McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 2007; 44 (04) (Suppl. 05) S3-S11
    CrossrefPubMedGoogle Scholar
  • 47 Tomiyama Y, Kosugi S. Autoantigenic epitopes on platelet glycoproteins. Int J Hematol 2005; 81 (02) 100-105
    CrossrefPubMedGoogle Scholar
  • 48 Kiyomizu K, Kashiwagi H, Nakazawa T. , et al. Recognition of highly restricted regions in the β-propeller domain of αIIb by platelet-associated anti-αIIbβ3 autoantibodies in primary immune thrombocytopenia. Blood 2012; 120 (07) 1499-1509
    PubMedGoogle Scholar
  • 49 van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood 1982; 59 (01) 23-26
    CrossrefPubMedGoogle Scholar
  • 50 Fujisawa K, Tani P, O'Toole TE, Ginsberg MH, McMillan R. Different specificities of platelet-associated and plasma autoantibodies to platelet GPIIb-IIIa in patients with chronic immune thrombocytopenic purpura. Blood 1992; 79 (06) 1441-1446
    CrossrefPubMedGoogle Scholar
  • 51 Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood 1993; 81 (05) 1246-1250
    CrossrefPubMedGoogle Scholar
  • 52 McMillan R, Lopez-Dee J, Loftus JC. Autoantibodies to alpha(IIb)beta(3) in patients with chronic immune thrombocytopenic purpura bind primarily to epitopes on alpha(IIb). Blood 2001; 97 (07) 2171-2172
    CrossrefPubMedGoogle Scholar
  • 53 Roark JH, Bussel JB, Cines DB, Siegel DL. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood 2002; 100 (04) 1388-1398
    CrossrefPubMedGoogle Scholar
  • 54 van Bladel ER, Laarhoven AG, van der Heijden LB. , et al. Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. Blood 2014; 123 (10) 1556-1563
    CrossrefPubMedGoogle Scholar
  • 55 Frelinger III AL, Grace RF, Gerrits AJ, Carmichael SL, Forde EE, Michelson AD. Platelet function in ITP, independent of platelet count, is consistent over time and is associated with both current and subsequent bleeding severity. Thromb Haemost 2018; 118 (01) 143-151
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus 2011; 9 (03) 262-273
    PubMedGoogle Scholar
  • 57 Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009; 113 (14) 3154-3160
    CrossrefPubMedGoogle Scholar
  • 58 Asahi A, Nishimoto T, Okazaki Y. , et al. Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest 2008; 118 (08) 2939-2949
    PubMedGoogle Scholar
  • 59 Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291 (5503): 484-486
    CrossrefPubMedGoogle Scholar
  • 60 Tsubakio T, Tani P, Curd JG, McMillan R. Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol 1986; 63 (02) 293-300
    PubMedGoogle Scholar
  • 61 Peerschke EI, Andemariam B, Yin W, Bussel JB. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol 2010; 148 (04) 638-645
    CrossrefPubMedGoogle Scholar
  • 62 Najaoui A, Bakchoul T, Stoy J. , et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol 2012; 88 (02) 167-174
    CrossrefPubMedGoogle Scholar
  • 63 Bakchoul T, Greinacher A, Sachs UJ. , et al. Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia. Blood 2013; 122 (03) 321-327
    PubMedGoogle Scholar
  • 64 Bakchoul T, Walek K, Krautwurst A. , et al. Glycosylation of autoantibodies: insights into the mechanisms of immune thrombocytopenia. Thromb Haemost 2013; 110 (06) 1259-1266
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006; 4 (11) 2377-2383
    CrossrefPubMedGoogle Scholar
  • 66 Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000; 96 (07) 2520-2527
    CrossrefPubMedGoogle Scholar
  • 67 Webster ML, Sayeh E, Crow M. , et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006; 108 (03) 943-946
    PubMedGoogle Scholar
  • 68 Li J, van der Wal DE, Zhu G. , et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015; 6: 7737
    CrossrefPubMedGoogle Scholar
  • 69 Tao L, Zeng Q, Li J. , et al. Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia. J Hematol Oncol 2017; 10 (01) 46
    CrossrefPubMedGoogle Scholar
  • 70 Li J, Sullivan JA, Ni H. Pathophysiology of immune thrombocytopenia. Curr Opin Hematol 2018; 25 (05) 373-381
    CrossrefPubMedGoogle Scholar
  • 71 Quach ME, Dragovich MA, Chen W. , et al. Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. Blood 2018; 131 (07) 787-796
    CrossrefPubMedGoogle Scholar
  • 72 Mason KD, Carpinelli MR, Fletcher JI. , et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128 (06) 1173-1186
    CrossrefPubMedGoogle Scholar
  • 73 Li C, Piran S, Chen P. , et al. The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011; 121 (11) 4537-4547
    CrossrefPubMedGoogle Scholar
  • 74 van Der Wal DE, Zhu G, Li J. , et al. Desialylation: a novel platelet clearance mechanism and a potential new therapeutic target in Anti-GPIb antibody mediated thrombocytopenia. Blood 2012; 120 (21) 265
    CrossrefPubMedGoogle Scholar
  • 75 Leytin V, Mykhaylov S, Starkey AF. , et al. Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol 2006; 133 (01) 78-82
    PubMedGoogle Scholar
  • 76 Alvarez Román MT, Fernández Bello I, Arias-Salgado EG. , et al. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thromb Haemost 2014; 112 (01) 65-72
    Article in Thieme ConnectPubMedGoogle Scholar
  • 77 Winkler J, Kroiss S, Rand ML. , et al. Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin. Br J Haematol 2012; 156 (04) 508-515
    CrossrefPubMedGoogle Scholar
  • 78 Goette NP, Glembotsky AC, Lev PR. , et al. Platelet apoptosis in adult immune thrombocytopenia: insights into the mechanism of damage triggered by auto-antibodies. PLoS One 2016; 11 (08) e0160563
    CrossrefPubMedGoogle Scholar
  • 79 Grozovsky R, Begonja AJ, Liu K. , et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 2015; 21 (01) 47-54
    CrossrefPubMedGoogle Scholar
  • 80 Xu M, Li J, Neves MAD. , et al. GPIbα is required for platelet-mediated hepatic thrombopoietin generation. Blood 2018; 132 (06) 622-634
    PubMedGoogle Scholar
  • 81 Machlus KR, Italiano Jr JE. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol 2013; 201 (06) 785-796
    CrossrefPubMedGoogle Scholar
  • 82 Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995; 85 (07) 1719-1726
    CrossrefPubMedGoogle Scholar
  • 83 Dameshek W, Miller EB. The megakaryocytes in idiopathic thrombocytopenic purpura, a form of hypersplenism. Blood 1946; 1: 27-50
    CrossrefPubMedGoogle Scholar
  • 84 Rolovic Z, Baldini M, Dameshek W. Megakaryocytopoiesis in experimentally induced immune thrombocytopenia. Blood 1970; 35 (02) 173-188
    CrossrefPubMedGoogle Scholar
  • 85 McMillan R, Luiken GA, Levy R, Yelenosky R, Longmire RL. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA 1978; 239 (23) 2460-2462
    CrossrefPubMedGoogle Scholar
  • 86 Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 1999; 93 (06) 1951-1958
    CrossrefPubMedGoogle Scholar
  • 87 Chang M, Nakagawa PA, Williams SA. , et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102 (03) 887-895
    CrossrefPubMedGoogle Scholar
  • 88 McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103 (04) 1364-1369
    CrossrefPubMedGoogle Scholar
  • 89 Iraqi M, Perdomo J, Yan F, Choi PY, Chong BH. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica 2015; 100 (05) 623-632
    CrossrefPubMedGoogle Scholar
  • 90 Zeng DF, Chen F, Wang S. , et al. Autoantibody against integrin αv β3 contributes to thrombocytopenia by blocking the migration and adhesion of megakaryocytes. J Thromb Haemost 2018; 16 (09) 1843-1856
    CrossrefPubMedGoogle Scholar
  • 91 Kuwana M, Okazaki Y, Kajihara M. , et al. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis Rheum 2002; 46 (08) 2148-2159
    CrossrefPubMedGoogle Scholar
  • 92 Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010; 47 (03) 243-248
    CrossrefPubMedGoogle Scholar
  • 93 Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76 (06) 628-638
    PubMedGoogle Scholar
  • 94 Mahévas M, Fain O, Ebbo M. , et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol 2014; 165 (06) 865-869
    CrossrefPubMedGoogle Scholar
  • 95 Saleh MN, Bussel JB, Cheng G. , et al; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121 (03) 537-545
    CrossrefPubMedGoogle Scholar
  • 96 Bal G, Fabian D, Maia D, Ringel F, Salama A. Effect of thrombopoietin receptor agonists on leukocyte and haematopoietic stem and progenitor cells in the peripheral blood of patients with immune thrombocytopenic purpura. Ann Hematol 2017; 96 (12) 2045-2056
    CrossrefPubMedGoogle Scholar
  • 97 Sheng GY, Huang XL, Bai ST. Expression levels of CXCR4 on megakaryocytes and its ligand in bone marrow in children with acute idiopathic thrombocytopenic purpura [in Chinese]. Zhonghua Er Ke Za Zhi 2004; 42 (07) 499-501
    PubMedGoogle Scholar
  • 98 Edelstein LC, Bray PF. MicroRNAs in platelet production and activation. Blood 2011; 117 (20) 5289-5296
    CrossrefPubMedGoogle Scholar
  • 99 Garzon R, Pichiorri F, Palumbo T. , et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A 2006; 103 (13) 5078-5083
    CrossrefPubMedGoogle Scholar
  • 100 Bay A, Coskun E, Oztuzcu S, Ergun S, Yilmaz F, Aktekin E. Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura. Blood Coagul Fibrinolysis 2014; 25 (04) 379-383
    CrossrefPubMedGoogle Scholar
  • 101 Basciano PA, Bussel J, Hafeez Z, Christos PJ, Giannakakou P. The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP). Br J Haematol 2013; 160 (02) 237-243
    CrossrefPubMedGoogle Scholar
  • 102 Yang L, Wang L, Zhao CH. , et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood 2010; 116 (20) 4307-4316
    PubMedGoogle Scholar
  • 103 Radley JM, Haller CJ. Fate of senescent megakaryocytes in the bone marrow. Br J Haematol 1983; 53 (02) 277-287
    CrossrefPubMedGoogle Scholar
  • 104 Houwerzijl EJ, Blom NR, van der Want JJ. , et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103 (02) 500-506
    CrossrefPubMedGoogle Scholar
  • 105 Arnold DM, Nazi I, Kelton JG. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. Expert Opin Investig Drugs 2009; 18 (06) 805-819
    CrossrefPubMedGoogle Scholar
  • 106 Vrbensky JR, Nazy I, Toltl LJ. , et al. Megakaryocyte apoptosis in immune thrombocytopenia. Platelets 2018; 29 (07) 729-732
    CrossrefPubMedGoogle Scholar
  • 107 Guo L, Kapur R, Aslam R. , et al. Antiplatelet antibody-induced thrombocytopenia does not correlate with megakaryocyte abnormalities in murine immune thrombocytopenia. Scand J Immunol 2018; 88 (01) e12678
    CrossrefPubMedGoogle Scholar
  • 108 Kim N, Im KI, Lim JY. , et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann Hematol 2013; 92 (10) 1295-1308
    CrossrefPubMedGoogle Scholar
  • 109 Xiao J, Zhang C, Zhang Y. , et al. Transplantation of adipose-derived mesenchymal stem cells into a murine model of passive chronic immune thrombocytopenia. Transfusion 2012; 52 (12) 2551-2558
    CrossrefPubMedGoogle Scholar
  • 110 Madonna R, Petrov L, Teberino MA. , et al. Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction. Cardiovasc Res 2015; 108 (01) 39-49
    CrossrefPubMedGoogle Scholar
  • 111 Mohanty ST, Kottam L, Gambardella A. , et al. Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis. Arthritis Res Ther 2010; 12 (04) R149
    CrossrefPubMedGoogle Scholar
  • 112 Li X, Liu L, Meng D. , et al. Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Stem Cells Dev 2012; 21 (13) 2387-2394
    CrossrefPubMedGoogle Scholar
  • 113 Bacigalupo A, Valle M, Podestà M. , et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005; 33 (07) 819-827
    CrossrefPubMedGoogle Scholar
  • 114 Zhang D, Li H, Ma L. , et al. The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. Autoimmunity 2014; 47 (08) 519-529
    CrossrefPubMedGoogle Scholar
  • 115 Pérez-Simón JA, Tabera S, Sarasquete ME. , et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy 2009; 11 (06) 698-705
    CrossrefPubMedGoogle Scholar
  • 116 Tao Y, Song D, Zhang F, Ren S, Zhang H, Sun L. Transplantation of bone-marrow-derived mesenchymal stem cells into a murine model of immune thrombocytopenia. Blood Coagul Fibrinolysis 2017; 28 (08) 596-601
    CrossrefPubMedGoogle Scholar
  • 117 Wang X, Yin X, Sun W. , et al. Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: a two-year follow-up. Exp Ther Med 2017; 13 (05) 2255-2258
    CrossrefPubMedGoogle Scholar